Anti-Angiogenic Treatment (Sunitinib) for Disseminated Malignant Haemangiopericytoma: A Case Study and Review of the Literature

Delgado, M; Pérez-Ruiz, Elísabeth; Alcalde, José; Pérez, David; Villatoro, R.; Rueda, A. Gómez

doi:10.1159/000324487

Cited by 17 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of chemotherapy in the treatment of the metastatic M-HPC remains controversial with varied responses in an extremely limited number of studies (9,14,17,18). Certain novel drugs, including anti-vascular endothelial growth factor receptor drugs (19)(20)(21) and a tyrosine kinase inhibitor (22), have been initiated to treat this disease. Temozolomide has demonstrated activity against numerous types of cancers (23)(24)(25).…”

Section: Discussionmentioning

confidence: 99%

Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs

Wei

Kang

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Regardless of the controversial pathogenesis, intracranial meningeal hemangiopericytoma (M-HPC) is a rare, highly cellular and vascularized mesenchymal tumor that is characterized by a high tendency for recurrence and extraneural metastasis, despite radical excision and postoperative radiotherapy. M-HPC shares similar clinical manifestations and radiological findings with meningioma, which causes difficulty in differentiation of this entity from those prognostically favorable mimics prior to surgery. Treatment of M-HPC, particularly in metastatic settings, remains a challenge. A case is described of primary M-HPC with recurrence at the initial and distant intracranial sites and extraneural multiple-organ metastases in a 36-year-old female. The metastasis of M-HPC was extremely extensive, and to the best of our knowledge this is the first case of M-HPC with delayed metastasis to the bilateral kidneys. The data suggests that preoperative computed tomography and magnetic resonance imaging could provide certain diagnostic clues and useful information for more optimal treatment planning. The results may imply that novel drugs, such as temozolomide and bevacizumab, as a component of multimodality therapy of M-HPC may deserve further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs

Wei

Kang

Liu

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Chemotherapy has shown some efficacy in metastatic disease. Adriamycin alone or in combination with other chemotherapy agents have been associated with complete or partial remission of disease in up to 50% of patients [1,11]. The efficacy of bevacizumab and temozolomide in metastatic HPC has been described in a population-based analysis with an overall response rate of 21.4%, and a median progression free survival of 17 months as previously reported [10].…”

Section: Discussionmentioning

confidence: 74%

Serial transarterial embolization for the management of unresectable malignant pulmonary hemangiopericytoma: A case report and review of the literature

Esber

Schwarze

Critchfield

et al. 2019

Respiratory Medicine Case Reports

View full text Add to dashboard Cite

Hemangiopericytomas (HPC) are perivascular neoplasms that are rarely encountered as primary lung malignancy. Surgical resection remains the mainstay therapy of HPC. A 37-year old African American female initially presented with fatigue, chest pain and palpitations. Chest radiography showed a well-circumscribed large heterogeneous vascular mass of the right hemithorax. She underwent a CT-guided biopsy of the thoracic mass and was diagnosed with low-grade pulmonary hemangiopericytoma. High tumor vascularity burden and liver metastases precluded her from being a surgical candidate. Three years ago, she referred to our facility seeking further management. She did not tolerate systemic chemotherapy. Alternatively, she had been successfully managed with serial transarterial embolization and oral angiogenesis inhibitor to date. This therapeutic approach can be further explored for long term control of unresectable pulmonary HPC.

show abstract

“…No evidence suggests that adjuvant chemotherapy is beneficial. If the HPC appears malignant histologically, adjuvant radiation therapy may be considered (6,7). Adjuvant therapy for this patient is limited as chemotherapy is ineffective and radiotherapy is not suitable for the thoracic cavity.…”

Section: Discussionmentioning

confidence: 99%

Hemangiopericytoma 11 years later: delayed recurrence of a rare soft tissue sarcoma

et al. 2017

View full text Add to dashboard Cite

Hemangiopericytomas (HPCs) are uncommon tumours. We present the case of a 41-year-old female with multiple resections at different sites over the course of 11 years. The approach considerations, as well as treatment options and prognosis are discussed. A 41-year-old female with two previous resections for intracranial meningeal HPC in 2004 and 2008, as well as adjuvant radiotherapy, presented in 2015 with left intrathoracic and left hip recurrence confirmed by positron emission tomography/computed tomography (PET/CT). She underwent left proximal femur resection/reconstruction and video-assisted thoracoscopic surgery (VATS) resection of the intrathoracic tumour was attempted. She was discharged home on her 4th post-operative day with minimal pain. There were no neurosensory or motor deficits. Any patient who has been diagnosed with HPC in the past who develops new symptoms should be worked up for recurrence, regardless of the length of disease-free interval, as our case study suggested. There has yet to be a standardized follow-up regime due to the rarity of these tumours. HPC remains a rare soft tissue sarcoma with high recurrence rate. Planned VATS evaluation and resection is possible provided complete resection with clear surgical margins can be achieved, as clear surgical margins offer the best chance of survival.

show abstract

Anti-Angiogenic Treatment (Sunitinib) for Disseminated Malignant Haemangiopericytoma: A Case Study and Review of the Literature

Cited by 17 publications

References 11 publications

Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs

Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs

Serial transarterial embolization for the management of unresectable malignant pulmonary hemangiopericytoma: A case report and review of the literature

Hemangiopericytoma 11 years later: delayed recurrence of a rare soft tissue sarcoma

Contact Info

Product

Resources

About